Article Details
Retrieved on: 2022-11-22 06:47:42
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In the face of the pandemic, Junshi ...
Article found on: www.wdrb.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here